Premium
Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia
Author(s) -
Silla Lucia,
Dulley Frederico,
Saboya Rosaura,
Kerbauy Fabio,
Moraes Arantes Adriano,
Pezzi Annelise,
Gross Luisa Grave,
Paton Eduardo,
Hamerschlak Nelson
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12808
Subject(s) - medicine , hematopoietic stem cell transplantation , myeloid leukemia , transplantation , leukemia , oncology , bone marrow
/Objectives Acute myeloid leukemia (AML) accounts for 90% of all cases of acute leukemia in adults. In Brazil, the mortality from myeloid leukemia is 1.74/100 000 men and 1.37/100 000 women. Our aim was to review and update guidelines of the Brazilian Society of Bone Marrow Transplantation on indications of hematopoietic stem cell transplantation (HSCT) for the treatment AML. Conclusions (i) Allo‐HSCT is recommended for high‐risk AML (IA); (ii) allo‐HSCT is recommended for AML of intermediate risk (IA); (iii) allo‐HSCT is recommended for AML relapsed/refractory (C4); (iv) auto‐HSCT is recommended for AML after 1 consolidation (C4); (v) auto‐HSCT is recommended for AML in CR1 (higher than QT in the Brazilian experience) (C4); (vi) auto‐HSCT is accepted for AML M3 in second molecular complete remission (2B); (vii) peripheral blood instead of Bone Marrow HSC for advanced disease (2A); (viii) recommended conditioning protocols: Bu‐Cy/Bu‐Mel, Bu‐Flu, TBI‐Cy. In umbilical cord HSCT, consider ATG‐based protocols (2A); (ix) allogeneic HSCT for the treatment of AML can be used in patients between 60 and 80 yr with good performance status and the absence of significant comorbidities (C4).